Signal Transduction and Targeted Therapy

Signal Transduction and Targeted Therapy is a premier open-access journal published by Springer Nature in partnership with the West China Hospital of Sichuan University. With an exceptional 2026 Impact Factor of 81.200, it stands among the highest-ranked journals globally, consistently placed in the JCR Q1 quartile. The journal’s scope encompasses the full spectrum of molecular and cellular mechanisms underlying signal transduction, with a particular emphasis on the identification and validation of novel therapeutic targets. It covers cutting-edge research in areas such as cancer biology, immunology, neurobiology, metabolic disorders, and cardiovascular disease, focusing on pathways including receptor tyrosine kinases, G protein-coupled receptors, immune checkpoints, and epigenetic regulators. The journal publishes a diverse array of article types, including original research articles, comprehensive reviews, perspectives, and brief communications, all of which undergo rigorous peer review. Its target audience includes academic researchers, clinical scientists, pharmacologists, and biotechnology professionals seeking the latest advances in targeted therapy development and translational medicine. Notable features include its fully open-access model, ensuring global visibility and unrestricted dissemination of findings, alongside rapid publication timelines and high editorial standards. As a leading voice in the field, Signal Transduction and Targeted Therapy serves as an essential resource for understanding fundamental signaling networks and their exploitation for precision medicine, reflecting its elite standing as one of the most influential and highly cited journals in biomedical research.